A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

The meeting, which helps the FDA give guidance to vaccine makers on which flu strains to target, is the second to be ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

Woven Health Collective elevates clients’ science, engages the right stakeholders, and magnifies success with a harmonized and highly specialized approach across key areas. All services are backed by ...

While announcing billions of dollars in new U.S. investments, David Ricks called for an extension of 2017 tax cuts and ...

The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a ...

CiteAb, a Sci-Tech company specialising in data collection, announces the launch of CiteAb Unlimited for pharmaceutical and biotechnology companies. This service provides private access to a database ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...